用于淋巴瘤早期高对比度抗体成像的生物正交化学方法
本研究报道四嗪敲除(TKO)方法,利用反式环辛烯-四嗪(TCO-Tz)反应,使完整放射性免疫偶联物在循环中积累于肿瘤后,通过化学触发裂解抗体与放射性之间的连接子,快速清除非靶组织放射性。在淋巴瘤模型中,Tz处理后24小时靶本比相较未处理组增加超过两倍,非靶器官放射性降低超过50%。
要点
- TKO方法利用TCO-Tz反应裂解连接子,快速清除循环中放射性抗体。
- 体外Tz处理30分钟内诱导超过70%的TCO连接子裂解。
- 淋巴瘤模型中Tz注射后24小时靶本比较未处理组增加超过两倍。
核心结论
- TKO方法有助于利妥昔单抗放射性免疫偶联物的早期成像,并具有用于淋巴瘤成像的转化潜力。
研究设计与样本
- 本研究为实验性方法学研究,优化TCO连接子并评估四嗪敲除循环抗体的放射性能力。
- 探索了多种细胞类型和具有不同内化速率的抗体以表征TKO参数。
- 在淋巴瘤模型中测试[89Zr]Zr-DFO-TCO-利妥昔单抗,并在Tz或载体给药后进行PET成像。
主要发现
- 体外Tz处理30分钟内诱导超过70%的TCO连接子裂解。
- 内化性放射性免疫偶联物在Tz处理下细胞摄取与载体相似,而缓慢内化抗体摄取降低。
- 啮齿类动物中Tz快速将放射性从抗体释放,从血液清除并积累于膀胱。
- Tz注射后TKO使非靶器官放射性降低超过50%。
- 在抗体内化速率较高的淋巴瘤模型中,肿瘤摄取未见降低,且24小时靶本比较未处理Tz组增加超过两倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monoclonal antibodies are highly specific for their targets making them effective for cancer therapy. However, their large molecular weight causes slow blood clearance, often requiring weeks to be removed from circulation. This limitation affects companion nuclear imaging and antibody-based diagnostics, necessitating delayed imaging. We report the expansion of a methodology improving positron emission tomography (PET) contrast of the lymphoma biomarker CD20 at early time points after radiolabeled antibody administration. Intact radioimmunoconjugates are allowed to stay in circulation long enough to accumulate in tumors, and then, using a chemical trigger, we induced rapid clearance of the radioactivity from non-target tissues by cleaving the linker between the antibody and the radioactivity. For brevity, we refer to the this as the Tetrazine KnockOut (TKO) method which uses the transcyclooctene-tetrazine (TCO-Tz) reaction, wherein an antibody is conjugated with linker containing TCO and a radioisotope. RESULTS: We optimized the TCO linker with several different radioisotopes and evaluated the ability of tetrazines to knockout radioactivity from circulating antibodies. We explored several cell types and antibodies with varying internalization rates, to characterize the parameters of TKO and tested [89Zr]Zr-DFO-TCO-rituximab in a lymphoma model with PET imaging after Tz or vehicle administration. Treatment with Tz induced > 70% cleavage of the TCO linker in vitro within 30 min. Internalizing radioimmunoconjugates exhibited similar cellular uptake with Tz compared to vehicle, whereas decreased uptake was seen with slowly internalizing antibodies. In rodents, Tz rapidly liberated the radioactivity from the antibody, cleared from the blood, and accumulated in the bladder. TKO resulted in > 50% decreased radioactivity in non-target organs following Tz injection. No decrease in tumor uptake was observed when rate of antibody internalization is higher in a lymphoma model, and the target-to-background ratio increased by > twofold in comparison with Tz nontreated groups at 24 h. CONCLUSION: The TKO approach potentiates early imaging of rituximab radioimmunoconjugates and has translational potential for lymphoma imaging.
引用
- Sarkar S, Pham JM, Edwards KJ, et al. A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time points. EJNMMI Res. 2025. PMID: 40122966. doi:10.1186/s13550-025-01213-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。